The World Health Organization (WHO) released guidelines for defending infants from respiratory syncytial virus (RSV), according to an announcement.
The article, titled WHO position paper on immunization to protect infants against respiratory syncytial virus disease, details WHO’s suggestions for RSV vaccines for mothers and infants.
WHO says that all countries should “introduce either the maternal vaccine, RSVpreF, or the monoclonal antibody, nirsevimab depending on the feasibility of implementation within each country’s existing health system, cost-effectiveness and anticipated coverage.” They suggest women get the RSVpreF vaccine after 28 weeks of pregnancy.
WHO recommends nirsevimab for infants under 6 months. They emphasize the vaccine should be given to a baby “right after birth or before being discharged from a birthing facility.” They give additional recommendations for if the vaccine is not available when a baby is born.
